CompletedNot Applicable

Progesterone Levels and Clinical Outcomes Using a Single Pessary of 400 mg of Vaginal Progesterone in Substitutive Cycles for Embryo Transfer.

Spain347 participantsStarted 2021-03-03

Plain-language summary

This study aims to compare the efficacy, in terms of progesterone levels and clinical outcomes, of two different presentations of micronized vaginal progesterone (400 mg vs. 200 mg) used in endometrial preparation in artificial cycle (AC) for embryo transfer. This is a non-inferiority, retrospective case-control study, with at least 200 cycles analyzed (at least 100 per arm) and the primary outcome is the serum progesterone level on the day of the embryo transfer.

Who can participate

Age range18 Years – 50 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with primary or secondary infertility undergoing endometrial preparation for an embryo transfer using standard doses of oral or transdermal estrogens. * Age between 18 and 50 years. * Normal uterine cavity verified by imaging techniques. * Serum progesterone documented on the day of embryo transfer. Exclusion Criteria: * Patients with a history of endometritis. * Patients diagnosed with Asherman's syndrome. * Patients with a different supplementation regimen or doses than those of the study groups.

What they're measuring

Serum progesterone level

Timeframe: On the day of embryo transfer

Trial details

NCT IDNCT04722471

SponsorInstituto Bernabeu

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-03-03

View on ClinicalTrials.gov More Luteal Phase Defect trials